Datum Dental Ltd, a subsidiary of Datum Biotech, was founded in order to develop, manufacture and market a full line of biomaterial products for dental tissue and bone regeneration.
Datum Dental develops sugar cross‐linked collagen products in different forms for dental regeneration. These products are designed to cover a wide range of bone and soft tissue dental regenerative requirements.
The Company’s leading product, OSSIX® PLUS is a GLYMATRIX™ technology based cross-linked collagen membrane. It was cleared for sale in the U.S. by the FDA in 2006, , and obtained CE marking, as well as other certifications granted worldwide for guided bone regeneration (GBR) and guided tissue regeneration (GTR).
Datum's technology and regenerative collagen products in development aim to solve some of the biggest deficiencies in biomaterial‐based products in use today, including insufficient bone or soft tissue regeneration, poor healing, or poor recovery of wounds and fractures.
By using its unique and clinically proven cross‐linking GLYMATRIX™ technology, Datum strives to overcome the majority of these deficiencies in various medical markets. The Company’s proprietary technology and ongoing research and development place Datum Biotech and Datum Dental at the forefront of bio-programming, paving the way to become world class players in the field of biomaterials.
Datum has acquired all intellectual property rights and knowhow, including: technology, patents, trademarks, manufacturing and R&D data of Colbar Life Science from Johnson & Johnson (J&J), including related regulatory files.
Furthermore, Datum has continued to develop this technology by contributing new qualities and attributes to the current products, as well as expanding the Company’s product portfolio.
The Company's headquarters includes an ISO 13485 certified, GMP facility with clean rooms, located in Israel, a hub of biomed and biotech innovation.
For additional information please contact us.